The PERISCOPE II study in patients with gastric cancer and limited peritoneal metastases: lessons learned

Authors: van Sandick, J W; Quik, J S E; Vollebergh, M A

Source journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026-10-29)

DOI: 10.1016/j.ejso.2026.112338

Abstract

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has long been regarded as a promising strategy for gastric cancer with limited peritoneal metastases, despite the absence of randomised evidence. The PERISCOPE II study now provides prospective data to fill this gap in the literature. Between 2017 and 2024, 102 patients with resectable cT3-cT4a gastric adenocarcinoma and limited peritoneal disease (PCI <7) and/or tumour-positive cytology were randomised in the absence of disease progression after initial chemotherapy to either continuation of systemic therapy or gastrectomy with CRS/HIPEC. No survival advantage emerged for CRS/HIPEC: median overall survival was 16.6 months (standard arm) versus 15.7 months (experimental arm; HR 1.10), after 67-month median follow-up. Serious adverse events occurred in 44% of the surgical arm versus 6% of the standard arm. There were three treatment-related deaths, all in the experimental arm. Clinically, gastrectomy with CRS/HIPEC should not be offered to patients with gastric cancer and limited peritoneal metastases outside the context of clinical trials. In this lessons learned article, we discuss the strengths and limitations of the PERISCOPE II study, the implications and added benefit of negative trials, as well as the alternative approaches for future research.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.